All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Musculoskeletal Product Name: Xeljanz
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2020
Details:
The study met its primary and key secondary endpoint of Assessment in SpondyloArthritis International Society (ASAS) 20 and 40 response, respectively, compared to placebo at week 16.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PF-06939926
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
The preliminary data from 9 ambulatory boys with DMD, aged 6 to 12 indicate that the intravenous administration of PF-06939926 was well-tolerated during the infusion period, with encouraging efficacy and manageable safety events.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PF-06939926
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2020
Details:
First ever Phase III gene therapy clinical trial for Duchenne muscular dystrophy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegadricase
Therapeutic Area: Musculoskeletal Product Name: SEL-212
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 23, 2020
Details:
Selecta Biosciences, 3SBio partner, has commenced the phase III clinical program of a combination therapy involving SEL-212 for the treatment of chronic refractory gout on behalf of SobiTM, and has made a milestone payment of USD 4 million to 3SBio.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tolperisone
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
The published clinical data demonstrates the potential benefit of tolperisone in the treatment of acute and painful muscle spasms. The data supports and strengthens a planned Phase 3 RESUME-1 study, for which Neurana will begin enrollment imminently.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JTA-004
Therapeutic Area: Musculoskeletal Product Name: JTA-004
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
The JTA-004 Phase III study is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading current osteoarthritis treatment on the market.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegadricase
Therapeutic Area: Musculoskeletal Product Name: SEL-212
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Patients with tophi showed a substantially higher overall response rate for SEL-212 versus pegloticase and a statistically significant overall reduction in mean SUA levels for SEL-212 versus pegloticase.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cyclobenzaprine Hydrochloride
Therapeutic Area: Musculoskeletal Product Name: TNX-102 SL
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
Tonix is currently enrolling into a second potentially pivotal Phase 3 trial, F306 or the RALLY study, to study TNX-102 SL for the management of fibromyalgia, with topline data expected in the second half of 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal Product Name: Zilosul
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
Positive feedback has been received from European Medicines Agency after Paradigm’s recent Scientific Advice meeting, a key regulatory milestone which supports and validates the company’s clinical development and commercialisation plans for Zilosul® in Europe.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pegadricase
Therapeutic Area: Musculoskeletal Product Name: SEL-212
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
The phase 3 DISSOLVE clinical programme a randomized double-blind, placebo-controlled study in which SEL-212 will be evaluated at two doses of ImmTOR, and one dose of pegadricase in both studies.